Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids)
Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
09/2003
09/02/2003US6613770 Quinoline derivatives as NK-2 and NK-3 receptor ligands
09/02/2003US6613769 Tryptase inhibitors
09/02/2003US6613760 Indole derivatives and their use as MCP-1 receptor antagonists
09/02/2003US6613746 Cell adhesion proteins having cells with glycoprotein antibodies and carbohydrate determinants used to interfere with binding FC receptor and as complement inhibitors; antiinflammatory agents
09/02/2003US6613361 Ketoprofen microgranules, method for preparing same and pharmaceutical compositions
09/02/2003US6613322 Administering enzyme inhibitors
08/2003
08/28/2003WO2003070970A2 RNA INTERFERENCE MEDIATED INHIBITION OF NF-KAPPA B/REL-A GENE EXPRESSION USING SHORT INTERFEREING NUCLEIC ACID (siNA)
08/28/2003WO2003070969A2 RNA INTERFERENCE MEDIATED INHIBITION OF BCL2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070968A2 RNA INTERFERENCE MEDIATED INHIBITION OF GASTRIC INHIBITORY POLYPEPTIDE (GIP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070921A1 METHODS FOR PRODUCING Ϝδ T CELLS
08/28/2003WO2003070918A2 Rna interference by modified short interfering nucleic acid
08/28/2003WO2003070914A2 RNA INTERFERENCE MEDIATED INHIBITION OF FOS GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070911A2 Rna interference mediated inhibition of type 1 insulin-like growth factor receptor (igf-1r)
08/28/2003WO2003070905A2 Electroporation methods for introducing bioactive agents into cells
08/28/2003WO2003070903A2 RNA INTERFERENCE MEDIATED INHIBITION OF GRB2-ASSOCIATED BINDING PROTEIN 2 (GAB2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070897A2 RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR SUPERFAMILY GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070886A2 Inhibition of protein tyrosine phosphatase type iva expression byshort interfering nucleic acid
08/28/2003WO2003070881A2 RNA INTERFERENCE MEDIATED INHIBITION OF PROTEIN TYPROSINE PHOSPHATASE-1B (PTP-1B) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070767A1 Tissue specific expression
08/28/2003WO2003070761A1 Dual-effect ligands comprising anti-inflammatory hsp peptide epitopes for immunomodulation
08/28/2003WO2003070751A2 Partial peptide mimetics and methods
08/28/2003WO2003070744A1 RNA INTERFERENCE MEDIATED INHIBITION OF INTERLEUKIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
08/28/2003WO2003070730A1 Pyrrolopyrimidine derivative
08/28/2003WO2003070729A1 Pyrrolopyrimidine derivatives
08/28/2003WO2003070727A1 Thiazolyl urea compounds for the treatment of cancer
08/28/2003WO2003070716A1 Vitamin d3 derivatives and remedies using the same
08/28/2003WO2003070711A1 Oxa- and thiadiazoles and their use as metalloproteinase inhibitors
08/28/2003WO2003070709A1 Novel phenylalanine derivative
08/28/2003WO2003070707A1 Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
08/28/2003WO2003070706A1 Tricyclic pyrazole derivatives for the treatment of inflammation
08/28/2003WO2003070701A2 Syntheses of quinazolinones
08/28/2003WO2003070686A1 Substituted phenylalkanoic acid derivative and use thereof
08/28/2003WO2003070262A1 Pharmacological composition based on biologically active substances obtained from tribulus terrestris l
08/28/2003WO2003070261A1 Pharmacological substance from the plant tribulus terrestris
08/28/2003WO2003070251A1 Pharmaceutical combinations of cox-2 inhibitors and opiates
08/28/2003WO2003070249A1 Combination consisting of trapidil and serotonin antagonists such as cyproheptadine or pizotifen for inhibiting angiogenesis
08/28/2003WO2003070242A1 Piperidin-4-yl urea derivatives and related compounds as chemokine receptor inhibitors for the treatment of inflammatory diseases
08/28/2003WO2003070237A1 Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
08/28/2003WO2003070235A1 Medicinal compositions for inhibiting tryptase
08/28/2003WO2003070219A1 Drug delivery system for the subconjunctival administration of fine grains
08/28/2003WO2003070192A2 Compositions and methods for surrogate antibody modulation of an immune response and transport
08/28/2003WO2003070190A2 Surrogate antibodies and methods of preparation and use thereof
08/28/2003WO2003070188A2 Method of treating trx mediated diseases
08/28/2003WO2003070166A2 Novel tyloindicines and related processes, pharmaceutical compositions and methods
08/28/2003WO2003069997A1 Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins
08/28/2003WO2003055911A3 Cystine-knot fold protein
08/28/2003WO2003053158A3 Malleable protein matrix and uses thereof
08/28/2003WO2003049698A3 Substituted hydrazones as inhibitors of cyclooxygenase-2
08/28/2003WO2003037384A3 Polymer conjugates of protein kinase c inhibitors
08/28/2003WO2003031447A3 Pyrimidine derivatives
08/28/2003WO2003029217A3 Pyridinic sulfonamide derivatives, method of production and use thereof
08/28/2003WO2003025015A3 A soluble toll-like receptor
08/28/2003WO2003016335A3 Irreversible cysteine protease inhibitors of legumain
08/28/2003WO2003016285A8 Method of preparing 4-(imidazole-1-il)benzenesulphonamide derivatives
08/28/2003WO2003013434A3 Methods and compositions for treating diseases associated with excesses in ace
08/28/2003WO2003002058A3 Bone anabolic compounds and methods of use
08/28/2003WO2002097044A3 Alternative splice forms of proteins as basis for multiple therapeutic modalities
08/28/2003WO2002094192A3 Antibodies against tumor necrosis factor delta (april)
08/28/2003WO2002081521A3 Osteoprotegerin in milk
08/28/2003WO2002072534A3 1-butane acid derivatives, pharmaceutical compositions containing said derivatives and the use thereof
08/28/2003WO2002034940A3 Methods for screening compounds that modulate lipid metabolism
08/28/2003WO2002015885A3 Oral fast-melt formulation of a cyclooxygenase-2 inhibitor
08/28/2003WO2002012326A3 Mechanism of conditional regulation of the hypoxia-inducible factor-1 by the von hippel-lindau tumor suppressor protein
08/28/2003WO2001095859A3 Novel heterocyclic analogs of diphenylethylene compounds
08/28/2003US20030163845 Elongase genes and uses thereof
08/28/2003US20030163834 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of Erk-5
08/28/2003US20030162968 1,4-Disubstituted benzo-fused urea compounds
08/28/2003US20030162967 Having antithrombotic effect; fortherapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses; reversible inhibitors of blood clotting enzymes factor Xa and/or factor VIIa
08/28/2003US20030162964 Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient
08/28/2003US20030162814 Amines such as 2-(3-(N-hydroxyamidino)phenylamino)-N-(2'-sulfamoylbiphenyl-4-yl)-2 -methylpropionamide, used as anticoagulants or for prophylaxis of arteriosclerosis, angina pectoris, restinosis or metastasis
08/28/2003US20030162813 Heterocyclic nitrogen comppounds such as 4-(5-methyl-3-phenyl-isoxazol-1-yl)benzenesulfonamide, used as non-steroidal antiinflammatory agents or antiarthritic agents; cyclooxygenase inhibitors
08/28/2003US20030162811 Heterocyclic amines such as 4-(3'-Thienyl)-alpha, alpha, 1-trimethyl-4-piperidinemethanol and/or prodrugs, used as analgesics for prophylaxis of neuropathic pain
08/28/2003US20030162802 Preferential enzyme inhibitors such as 2-((4-6-pyrimidinedion -2-yl)amino)-4-methyl-5-thiazolecarboxylic acid ethyl ester, used for prophylaxis of lymphocyte associated disorders
08/28/2003US20030162801 Tricyclic compounds and their uses
08/28/2003US20030162799 Squaric acid derivatives
08/28/2003US20030162794 Benzazole derivatives and their use as jnk modulators
08/28/2003US20030162779 4-oxo-4H-thiazole derivative for treating or preventing neurodegenerative disorders
08/28/2003US20030162778 Carbocyclic side chain containing metalloprotease inhibitors
08/28/2003US20030162775 Heterocyclic substituted pyrazolones
08/28/2003US20030162772 For example, N-(2-(3-((1-(3,4-dichlorobenzylpiperidinyl) aminohydroxypropoxy)phenyl)acetamide; use as modulators of chemokine receptor activity, and may be used in treatment of autoimmune, inflammatory, proliferative diseases
08/28/2003US20030162771 Have an antagonistic activity with respect to corticotropin releasing factor
08/28/2003US20030162767 Novel 1,3-dihydro-2h-indol-2-one derivatives, method for preparing same and pharmaceutical compositions containing them
08/28/2003US20030162765 Use in treatment and prevention of central nervous system and other disorders
08/28/2003US20030162759 Preventing or treating cardiovascular disease including atherosclerosis
08/28/2003US20030162748 Comprises liposomes attached to prodrugs through phosphonate linkages; phospholipases; targets liver/spleen
08/28/2003US20030162744 Salmon-origin chondroitin sulfate
08/28/2003US20030162736 Medicament comprising NK4 gene or recombinant NK4 protein
08/28/2003US20030162709 Methods of generating multispecific, multivalent agents from VH and VL domains
08/28/2003US20030162300 Galactomannan-oligosaccharides and methods for the production and use thereof
08/28/2003US20030162252 Isolating cDNAs encoding novel G protein-coupled receptor proteins derived from human spleen
08/28/2003US20030162206 Central nervous system disorders; antiinflammatory agnets; antidiabetic agents
08/28/2003US20030162196 Isolation nucleic acids; genetic engineering; diagnosis, therapy, prevention hematopoietic, nervous system disorders
08/28/2003US20030162194 Diagnosis of diseases associated with apoptosis
08/28/2003US20030162175 NK cell receptor polynucleotides, polypeptides, and antibodies
08/28/2003US20030161884 Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base
08/28/2003US20030161867 Skin-permeable selective cyclooxygenase-2 inhibitor composition
08/28/2003US20030161863 Administering mixtures of nutrients for prophylaxis of muscular, metabolic or respiratory disorders, injuries, inflammation and/or to relieve stress
08/28/2003US20030161846 Oral administration of an emulsion pre-concentrate of a nitrogen oxide-releasing NSAID, a surfactant, and an oil or fat; forms an oil-in-water emulsion with gastrointestinal fluids; side- effect reduction; bioavailability
08/28/2003US20030161826 Therapy for autoimmune disease; central nervous system disorders
08/28/2003CA2477191A1 Immunostimulant compositions comprising aminoalkyl glucosaminide phosphates and saponins
1 ... 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 ... 1272